Global Dermatomycoses Drug Market Insights, Forecast to 2025
Table of Contents
1 Study Coverage
- 1.1 Dermatomycoses Drug Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Dermatomycoses Drug Market Size Growth Rate by Product
- 1.4.2 BB-2603
- 1.4.3 Clotrimazole
- 1.4.4 Dapaconazole
- 1.4.5 Others
- 1.5 Market by End User
- 1.5.1 Global Dermatomycoses Drug Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Dermatomycoses Drug Market Size
- 2.1.1 Global Dermatomycoses Drug Revenue 2014-2025
- 2.1.2 Global Dermatomycoses Drug Sales 2014-2025
- 2.2 Dermatomycoses Drug Growth Rate by Regions
- 2.2.1 Global Dermatomycoses Drug Sales by Regions
- 2.2.2 Global Dermatomycoses Drug Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Dermatomycoses Drug Sales by Manufacturers
- 3.1.1 Dermatomycoses Drug Sales by Manufacturers
- 3.1.2 Dermatomycoses Drug Sales Market Share by Manufacturers
- 3.1.3 Global Dermatomycoses Drug Market Concentration Ratio (CR5 and HHI)
- 3.2 Dermatomycoses Drug Revenue by Manufacturers
- 3.2.1 Dermatomycoses Drug Revenue by Manufacturers (2014-2019)
- 3.2.2 Dermatomycoses Drug Revenue Share by Manufacturers (2014-2019)
- 3.3 Dermatomycoses Drug Price by Manufacturers
- 3.4 Dermatomycoses Drug Manufacturing Base Distribution, Product Types
- 3.4.1 Dermatomycoses Drug Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Dermatomycoses Drug Product Type
- 3.4.3 Date of International Manufacturers Enter into Dermatomycoses Drug Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Dermatomycoses Drug Sales by Product
- 4.2 Global Dermatomycoses Drug Revenue by Product
- 4.3 Dermatomycoses Drug Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Dermatomycoses Drug Breakdown Data by End User
6 North America
- 6.1 North America Dermatomycoses Drug by Countries
- 6.1.1 North America Dermatomycoses Drug Sales by Countries
- 6.1.2 North America Dermatomycoses Drug Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Dermatomycoses Drug by Product
- 6.3 North America Dermatomycoses Drug by End User
7 Europe
- 7.1 Europe Dermatomycoses Drug by Countries
- 7.1.1 Europe Dermatomycoses Drug Sales by Countries
- 7.1.2 Europe Dermatomycoses Drug Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Dermatomycoses Drug by Product
- 7.3 Europe Dermatomycoses Drug by End User
8 Asia Pacific
- 8.1 Asia Pacific Dermatomycoses Drug by Countries
- 8.1.1 Asia Pacific Dermatomycoses Drug Sales by Countries
- 8.1.2 Asia Pacific Dermatomycoses Drug Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Dermatomycoses Drug by Product
- 8.3 Asia Pacific Dermatomycoses Drug by End User
9 Central & South America
- 9.1 Central & South America Dermatomycoses Drug by Countries
- 9.1.1 Central & South America Dermatomycoses Drug Sales by Countries
- 9.1.2 Central & South America Dermatomycoses Drug Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Dermatomycoses Drug by Product
- 9.3 Central & South America Dermatomycoses Drug by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Dermatomycoses Drug by Countries
- 10.1.1 Middle East and Africa Dermatomycoses Drug Sales by Countries
- 10.1.2 Middle East and Africa Dermatomycoses Drug Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Dermatomycoses Drug by Product
- 10.3 Middle East and Africa Dermatomycoses Drug by End User
11 Company Profiles
- 11.1 Anacor Pharmaceuticals Inc
- 11.1.1 Anacor Pharmaceuticals Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Products Offered
- 11.1.5 Anacor Pharmaceuticals Inc Recent Development
- 11.2 Biolab Farmaceutica Ltda
- 11.2.1 Biolab Farmaceutica Ltda Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Products Offered
- 11.2.5 Biolab Farmaceutica Ltda Recent Development
- 11.3 Blueberry Therapeutics Ltd
- 11.3.1 Blueberry Therapeutics Ltd Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Products Offered
- 11.3.5 Blueberry Therapeutics Ltd Recent Development
- 11.4 Daewoong Pharmaceutical Co Ltd
- 11.4.1 Daewoong Pharmaceutical Co Ltd Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Products Offered
- 11.4.5 Daewoong Pharmaceutical Co Ltd Recent Development
- 11.5 Dermala Inc
- 11.5.1 Dermala Inc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Dermala Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Dermala Inc Dermatomycoses Drug Products Offered
- 11.5.5 Dermala Inc Recent Development
- 11.6 Helix BioMedix Inc
- 11.6.1 Helix BioMedix Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Helix BioMedix Inc Dermatomycoses Drug Products Offered
- 11.6.5 Helix BioMedix Inc Recent Development
- 11.7 Novan Inc
- 11.7.1 Novan Inc Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Novan Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Novan Inc Dermatomycoses Drug Products Offered
- 11.7.5 Novan Inc Recent Development
- 11.8 Sol-Gel Technologies Ltd
- 11.8.1 Sol-Gel Technologies Ltd Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Products Offered
- 11.8.5 Sol-Gel Technologies Ltd Recent Development
- 11.9 TGV-Laboratories
- 11.9.1 TGV-Laboratories Company Details
- 11.9.2 Company Business Overview
- 11.9.3 TGV-Laboratories Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 TGV-Laboratories Dermatomycoses Drug Products Offered
- 11.9.5 TGV-Laboratories Recent Development
- 11.10 Viamet Pharmaceuticals Inc
- 11.10.1 Viamet Pharmaceuticals Inc Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Products Offered
- 11.10.5 Viamet Pharmaceuticals Inc Recent Development
- 11.11 Vyome Biosciences Pvt Ltd
12 Future Forecast
- 12.1 Dermatomycoses Drug Market Forecast by Regions
- 12.1.1 Global Dermatomycoses Drug Sales Forecast by Regions 2019-2025
- 12.1.2 Global Dermatomycoses Drug Revenue Forecast by Regions 2019-2025
- 12.2 Dermatomycoses Drug Market Forecast by Product
- 12.2.1 Global Dermatomycoses Drug Sales Forecast by Product 2019-2025
- 12.2.2 Global Dermatomycoses Drug Revenue Forecast by Product 2019-2025
- 12.3 Dermatomycoses Drug Market Forecast by End User
- 12.4 North America Dermatomycoses Drug Forecast
- 12.5 Europe Dermatomycoses Drug Forecast
- 12.6 Asia Pacific Dermatomycoses Drug Forecast
- 12.7 Central & South America Dermatomycoses Drug Forecast
- 12.8 Middle East and Africa Dermatomycoses Drug Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Dermatomycoses Drug Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
The global Dermatomycoses Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dermatomycoses Drug market based on company, product type, end user and key regions.
This report studies the global market size of Dermatomycoses Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dermatomycoses Drug in these regions.
This research report categorizes the global Dermatomycoses Drug market by top players/brands, region, type and end user. This report also studies the global Dermatomycoses Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Anacor Pharmaceuticals Inc
Biolab Farmaceutica Ltda
Blueberry Therapeutics Ltd
Daewoong Pharmaceutical Co Ltd
Dermala Inc
Helix BioMedix Inc
Novan Inc
Sol-Gel Technologies Ltd
TGV-Laboratories
Viamet Pharmaceuticals Inc
Vyome Biosciences Pvt Ltd
Market size by Product
BB-2603
Clotrimazole
Dapaconazole
Others
Market size by End User
Hospital
Clinic
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Dermatomycoses Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dermatomycoses Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dermatomycoses Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dermatomycoses Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Dermatomycoses Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dermatomycoses Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.